Market Place
Sourcing Support
GenSight Announces First GS010 Treatments in French AAC Program
20 Mar 2026 //
BUSSINESSWIRE
Gensight Biologics Provides Updates About GS010/LUMEVOQ Early
09 Mar 2026 //
BUSSINESSWIRE
GenSight Biologics Annual General Meeting on May 13, 2025
23 Apr 2025 //
BUSINESSWIRE
GenSight Reports June 30 Cash Position And Provides Business Update
22 Jul 2024 //
BUSINESSWIRE
GenSight Biologics Launches Newsletter for Retail Investors
11 Jul 2024 //
BUSINESSWIRE
GenSight Biologics Renegotiates Finances And Provides Operational Updates
20 Jun 2024 //
BUSINESSWIRE
GenSight Announces Update on Data from Early Access Programs of LUMEVOQ
06 Mar 2024 //
BUSINESSWIRE
GenSight Biologics Strengthens Its Team to Support the Launch of LUMEVOQ
12 Sep 2022 //
GENSIGHT-BIOLOGICS
GenSight Biologics reports 5 years’ data showing sustained efficacy and safety
20 Jul 2022 //
BUSINESSWIRE
GenSight Biologics Announces Publication of Study of the Impact of LHON Disease
18 May 2022 //
BUSINESSWIRE
GenSight seeks cash as gene therapy runway enters final year
09 Apr 2022 //
FIERCEBIOTECH
GenSight Biologics Reports Clinically Meaningful Vision Improvement
24 Jan 2022 //
BUSINESSWIRE
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ
14 Dec 2021 //
BUSINESSWIRE
GenSight Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ Injections
13 Dec 2021 //
BUSINESSWIRE
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes
29 Nov 2021 //
BUSINESSWIRE
GenSight Biologics to Host Key Opinion Leader Webcast on LUMEVOQ in US
22 Nov 2021 //
BUSINESSWIRE
GenSight Reports Second Patient Case Showing Significant Visual Recovery
17 Nov 2021 //
BUSINESSWIRE
Hiccup in manufacturing will cause GenSight to repeat the process
04 Nov 2021 //
ENDPTS
FDA Grants FTD to GenSight`s Optogenetic Therapy GS030 for Retinitis Pigmentosa
12 Oct 2021 //
BUSINESSWIRE
GenSight Biologics Announces FDA Grant of Fast Track Designation
12 Oct 2021 //
BUSINESSWIRE
GenSight Announces Publication of Review of Gene Therapy Trials for LHON
06 Oct 2021 //
BIOSPACE
GenSight Biologics Announces +ve Data Safety Review of PIONEER Ph I/II GS030
14 Sep 2021 //
SHARECAST
GenSight Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects
09 Sep 2021 //
BUSINESSWIRE
MHRA grants promising innovative medicine status to GenSight’s Lumevoq
08 Sep 2021 //
PHARMABIZ
UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
07 Sep 2021 //
BUSINESSWIRE
GenSight Biologics Announces Publication of RESTORE Study Data
31 Aug 2021 //
BUSINESSWIRE
GenSight Biologics Announces Approval of the LUMEVOQ® Cohort
06 Jul 2021 //
BUSINESSWIRE
GenSight granted Temporary Cohort Use Authorization (ATUc) for LUMEVOQ
06 Jul 2021 //
BUSINESSWIRE
GenSight announces positive results from phase III REFLECT trial of Lumevoq
02 Jul 2021 //
PHARMABIZ
GenSight`s gene therapy mystery continues
30 Jun 2021 //
ENDPTS
GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial
30 Jun 2021 //
BUSINESSWIRE
GenSight Biologics appoints Marion Ghibaudo as Technical Director
10 Jun 2021 //
BUSINESSWIRE
GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer
10 Jun 2021 //
PRESS RELEASE
GenSight Biologics Announces Nature Medicine Case Report Showing
25 May 2021 //
GENSIGHT-BIOLOGICS
GenSight Biologics Announces Nature Medicine Case Report Showing Visual
24 May 2021 //
BUSINESSWIRE
GenSight Biologics Reports Cash Position as of March 31, 2021 Operational Update
20 Apr 2021 //
BUSINESSWIRE
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/Iia
15 Feb 2021 //
BUSINESSWIRE
GenSight Biologics Announces Publication of Results from LUMEVOQ®
13 Jan 2021 //
BUSINESSWIRE
GenSight Biologics Announces Publication of Results from LUMEVOQ®
10 Dec 2020 //
BUSINESSWIRE
GenSight Biologics Announces Publication of Results from LUMEVOQ®
10 Dec 2020 //
BUSINESSWIRE
GENSIGHT BIOLOGICS REPORTS VALIDATION OF LUMEVOQ® MARKETING
03 Nov 2020 //
HEALTHCAP
GenSight Biologics Reports Validation of LUMEVOQ® (MAA) by EMA
02 Nov 2020 //
BUSINESSWIRE
GenSight Biologics Reports New Analysis Demonstrating Statistically Significant
21 Sep 2020 //
BLOOMBERG
GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ
15 Sep 2020 //
BIOSPACE
GenSight Biologics Reports Final REALITY Natural History Study Results
21 Jul 2020 //
BUSINESSWIRE
GenSight Biologics Obtains a €7m Non-Dilutive Loan and Renegotiates Agreement
09 Jul 2020 //
BUSINESSWIRE
GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients
06 Jul 2020 //
BUSINESSWIRE
GenSight Biologics on Track to Submit LUMEVOQ® for European Approval
15 Apr 2020 //
BUSINESSWIRE
GenSight Biologics Announces +ve Data Safety Board Review Phase I/II GS030
14 Apr 2020 //
BUSINESSWIRE
GenSight Biologics Announces Presentation Bilateral Visual Recovery From GS010
03 Mar 2020 //
BUSINESSINSIDER
